Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Pacira BioSciences, Inc.

Pacira BioSciences, Inc. (PCRX) Stock Overview

Explore Pacira BioSciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

PCRX●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$24.67
$0.84(3.52%)
U.S. Market opens in 58h 45m

Pacira BioSciences, Inc. (PCRX)

Meyka AI Score

Z

Key Financials

Market Cap970.4M
P/E Ratio69.41
EPS (TTM)$2.60
ROE0.02%
Fundamental Analysis

AI Price Forecasts

1 Month$27.85
3 Months$24.83
1 Year Target$22.95

PCRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Pacira BioSciences, Inc. (NASDAQ: PCRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Pacira BioSciences, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of PCRX on the NASDAQ shows an RSI of 49.02, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $22.95 for the NASDAQ listing.

Key metrics behind Pacira BioSciences, Inc.'s NASDAQ-traded stock include a P/E ratio of 69.41 and a market capitalization of 970.4M. Combined with our AI analysis, these give both institutional and retail investors a clear view of PCRX on the NASDAQ.

Price Performance (NASDAQ: PCRX)

1-Day Change
3.52%
5-Day Change
6.29%
1-Month Change
-4.31%
3-Month Change
5.07%
6-Month Change
6.24%
Year-to-Date (YTD) Change
-4.68%
1-Year Change
-2.84%
3-Year Change
-34.68%
5-Year Change
-57.92%
All-Time (Max) Change
251.42%

Contact Information

https://www.pacira.com
813 553 6680
2000 Sierra Point Parkway, Brisbane, CA, 94005

Company Facts

8,270 Employees
IPO DateFeb 3, 2011
CountryUS
Actively Trading

Frequently Asked Questions